Marchetti O, Lamoth F, Mikulska M, et al . ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases[J]. Bone Marrow Transplant,2012, 47(2):846-854.
[3]
Philippe B, Ibrahim-Granet O, Prévost M C, et al . Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates[J]. Infect Immun,2003, 71(7):3034-3042.
[4]
Lin S J, Schranz J, Teutsch S M. Aspergillosis case-fatality rate: Systematic review of the literature[J]. Clin Infect Dis,2001, 32(11):358-366.
[5]
Guinea J, Torres-Narbona M, Gijón P, et al . Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome[J]. Clin Microbiol Infect, 2010, 16(5):870-877.
[6]
Bulpa P A, Dive A M, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease[J]. Eur Respir J,2007, 30(9):782-800.
Muquim A, Dial S, Menzies D.Invasive aspergillosis in patients with chronic obstructive pulmonary diseases[J]. Can Respir J,2005, 12(6):199-204.
[9]
He H,Ding L,Li F, Zhan Q. Clinical features of invasive bronchialpulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study[J]. Crit Care,2011, 15:R5.
[10]
Metan G, Koç A N, Atalay A, et al . The peformance of galactomannan antigen assay in the diagnosis of invasive pulmonary aspergillosis at different cutoff values[J]. Mycoses,2011, 54(Suppl 2):80-81.
[11]
He H, Ding L, Chang S, et al . Value of consecutive galactomannan determinations for the diagnosis and prognosis of invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease[J]. Med Mycol,2011, 49(3):345-351.
[12]
Meersseman W, Vandecasteele S J, Wilmer A, et al .Invasive aspergillosis in critically ill patients without malignancy[J]. Am J Respir Crit Care Med,2004, 170(8):621-625.
[13]
Herbrecht R, Denning D W, Patterson T F, et al .Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002, 347(10):408-415.
[14]
Saito T, Fujiuchi S, Tao Y, et al . Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan[J]. Infection,2012, 40(2):661-667.
[15]
Chu H Y, Jain R, Xie H, et al . Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events[J]. BMC Infect Dis,2013, 13(4):105.
2017, Vol. 28 
